Thymosin Beta-4 Sulfoxide

While TB-500 acts primarily through actin binding to promote tissue repair and angiogenesis TB4-SO acts preferentially as an anti-inflammatory agent. It inhibits the migration and activation of inflammatory immune cells particularly macrophages and neutrophils to sites of inflammation. TB4-SO activates the NINJ1 pathway involved in cell survival under inflammatory stress and modulates NF-κB signaling to reduce pro-inflammatory cytokine production. Importantly TB4-SO does not bind actin with the same affinity as TB-500 suggesting its beneficial effects are mediated through entirely different molecular targets. The oxidation of methionine appears to shift the peptide's activity from tissue repair toward immune modulation making TB4-SO a potentially more targeted option for conditions where excessive inflammation rather than tissue damage is the primary concern.